Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Texas Health Science Center
mi
from
Houston, TX
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Glasgow - Western Infirmary
mi
from
Glasgow,
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Glasgow - Western Infirmary
mi
from
Glasgow,
Click here to add this to my saved trials
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/12/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/12/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Load Experienced While Using a Stander in Children With Cerebral Palsy
Load Experienced While Using a Stander in Children With Cerebral Palsy
Status: Enrolling
Updated:  2/15/2016
Clinical and Translational Science Institute at University of Minnesota
mi
from
Minneapolis, MN
Load Experienced While Using a Stander in Children With Cerebral Palsy
Load Experienced While Using a Stander in Children With Cerebral Palsy
Status: Enrolling
Updated: 2/15/2016
Clinical and Translational Science Institute at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Load Experienced While Using a Stander in Children With Cerebral Palsy
Load Experienced While Using a Stander in Children With Cerebral Palsy
Status: Enrolling
Updated:  2/15/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Load Experienced While Using a Stander in Children With Cerebral Palsy
Load Experienced While Using a Stander in Children With Cerebral Palsy
Status: Enrolling
Updated: 2/15/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
New Haven, CT
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Sacramento, CA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Aurora, CO
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Pompano Beach, FL
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigational Site
mi
from
Tampa, FL
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Atlanta, GA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
Baltimore, MD
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
Baltimore, MD
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Boston, MA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Detroit, MI
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
St. Louis, MO
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
New York, NY
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Stony Brook, NY
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Charlotte, NC
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Cleveland, OH
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Columbus, OH
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
Pittsburgh, PA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Burlington, VT
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Burlington, VT
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Charlottesville, VA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Seattle, WA
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Hobart,
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Hobart,
Click here to add this to my saved trials
REperfusion With Cooling in CerebraL Acute IscheMia II
REperfusion With Cooling in CerebraL Acute IscheMia II
Status: Enrolling
Updated:  2/16/2016
WellStar Kennestone Regional Medical Center
mi
from
Marietta, GA
REperfusion With Cooling in CerebraL Acute IscheMia II
REperfusion With Cooling in CerebraL Acute IscheMia II
Status: Enrolling
Updated: 2/16/2016
WellStar Kennestone Regional Medical Center
mi
from
Marietta, GA
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
North Central Neurology Associates, PC
mi
from
Cullman, AL
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
North Central Neurology Associates, PC
mi
from
Cullman, AL
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Xenoscience, Inc / 21st Century Neurology
mi
from
Phoenix, AZ
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Xenoscience, Inc / 21st Century Neurology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
HOPE Research Institute
mi
from
Phoenix, AZ
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Alta Bates Summit Medical Center - East Bay Physicians Medical Group
mi
from
Berkeley, CA
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Alta Bates Summit Medical Center - East Bay Physicians Medical Group
mi
from
Berkeley, CA
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Patricia A Fodor, PC
mi
from
Colorado Springs, CO
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Patricia A Fodor, PC
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Bradenton Neurology
mi
from
Bradenton, FL
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Bradenton Neurology
mi
from
Bradenton, FL
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Neurological Associates
mi
from
Pompano Beach, FL
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Neurological Associates
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Medical College of Georgia - Department of Neurology
mi
from
Augusta, GA
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Medical College of Georgia - Department of Neurology
mi
from
Augusta, GA
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Allied Physicians Inc
mi
from
Fort Wayne, IN
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Allied Physicians Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
MidAmerica Neuroscience Institute
mi
from
Lenexa, KA
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
MidAmerica Neuroscience Institute
mi
from
Lenexa, KA
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Associates in Neurology
mi
from
Lexington, KY
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Associates in Neurology
mi
from
Lexington, KY
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
St Mary's of Michigan - Field Neuroscience Institute
mi
from
Saginaw, MI
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
St Mary's of Michigan - Field Neuroscience Institute
mi
from
Saginaw, MI
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Ayres & Associates Clinical Trials
mi
from
Lebanon, NH
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Ayres & Associates Clinical Trials
mi
from
Lebanon, NH
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Winthrop University Hospital - Clinical Trials Unit
mi
from
Mineola, NY
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Winthrop University Hospital - Clinical Trials Unit
mi
from
Mineola, NY
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Neurology Consultants of the Carolinas, PA
mi
from
Charlotte, NC
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Neurology Consultants of the Carolinas, PA
mi
from
Charlotte, NC
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Neurology and Neuroscience Associates
mi
from
Akron, OH
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Neurology and Neuroscience Associates
mi
from
Akron, OH
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Neurological Research Institute
mi
from
Columbus, OH
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Neurological Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Neurology Specialists
mi
from
Dayton, OH
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Neurology Specialists
mi
from
Dayton, OH
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Providence St. Vincent Medical Center - Northwest MS Center
mi
from
Portland, OR
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Providence St. Vincent Medical Center - Northwest MS Center
mi
from
Portland, OR
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
The Maxine Mesinger MS Clinic/Baylor College of Medicine
mi
from
Houston, TX
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
The Maxine Mesinger MS Clinic/Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials